Reshaping the future of medicine.
Transforming care with precision medicine.
At Moleculera Biosciences, we believe in first identifying the biological cause of diseases, not just treating the symptoms. Our work in precision medicine focuses on understanding what’s occurring beneath the surface of complex conditions, including chronic neuropsychiatric and cardiovascular disorders, as well as Alzheimer’s disease. By examining the immune system’s role in these illnesses, we aim to uncover the underlying root causes. Once identified, this enables personalized treatments that can yield life-changing results.
Harnessing the power of real-world data to improve patients’ lives.
We are intently focused on the discovery and development of next-generation technologies for the identification, diagnosis, and treatment of patients suffering from immune-mediated disorders, including neuropsychiatric and cardiovascular disorders, as well as Alzheimer’s disease. Our unique technology platform comprises three integrated components, which, when used together, enable unprecedented discoveries. Moleculera’s platform includes: blood-based autoantibody testing panels, an expansive biorepository of phenotypically curated specimens, and a novel biomarker and targeted therapeutic identification program.
Blood Panel
Bioinformatics
Programs
Multiple Translational Programs
Moleculera Biosciences is advancing multiple translational programs to address the unmet needs of patients suffering from chronic, immune-mediated disorders, including neuropsychiatric and cardiovascular disorders, as well as Alzheimer’s disease. The company has a robust pipeline of multiple autoantibody panels, including the Autoimmune Brain Panel™ (our signature program already in the market), the Autoimmune Cardiovascular Panel™, and an Alzheimer’s Early Intervention Inflammatory Biomarker (AEIIB) Panel™.
Autoimmune
Brain Panel™
Autoimmune
Cardiovascular Panel™
Alzheimer’s Early
Intervention Inflammatory Biomarker Panel™
Improving patient care through precision testing.
The Autoimmune Brain Panel™ includes a series of five high-complexity blood tests that assists clinicians in determining whether a patient’s neuropsychiatric symptoms may be due to a treatable autoimmune dysfunction, rather than a primary neurologic or psychiatric illness. Once diagnosed and treated properly, patients often experience a complete resolution or dramatic reduction in symptoms.
Only test of its kind
Providing hope for patients with treatment-resistant neuropsychiatric conditions.
Approximately 800 million individuals worldwide 1 suffer from neurologic, psychiatric and behavioral disorders. Typically, patients are treated with psychotropic or anti-seizure medications. However, 20-60% of these patients do not respond to treatment 2. Research indicates that in some of these cases, patients do not improve because the root cause is immune-mediated and goes undiagnosed.
That’s all changing with the Autoimmune Brain Panel™ – the only commercially available test of its kind that assists clinicians in diagnosing and treating immune-mediated neuropsychiatric disorders.
Neuropsychiatric symptoms that may be caused by an autoimmune reaction
Empowering Science.
clinicians utilizing the platform
patients tested
years of research and development
Medical Resources For Healthcare Providers
We are committed to helping healthcare providers improve clinical outcomes for patients with treatment resistant neuropsychiatric symptoms.
Could your symptoms be due to an immune dysfunction?
Answer a few questions to find out if you might benefit from testing with the Autoimmune Brain Panel™.
IN THE NEWS
